Intratumoral Hypoxia Reduces IFN-γ–Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Tumor hypoxia occurs because of an increased demand for oxygen by the rapidly growing tumor cells, together with reduction in the oxygen supply due to malformed and nonfunctional tumor vasculature. The effects of tumor hypoxia on radiotherapy (RT) are well known; however, recent findings suggest it may also suppress immunotherapy, although the mechanisms governing this observation remain undetermined. Our laboratory and others have shown that IFN-γ conditions the tumor milieu and is important for the efficacy of RT. Thus, we hypothesized that hypoxia could inhibit IFN-γ–mediated antitumor responses, resulting in decreased RT efficacy. This inhibition could involve the production and/or the cellular response to IFN-γ. To test this, we used murine tumor cell lines B16F0 and Colon38. We observed that hypoxia inhibited upregulation of IFN-γ–dependent MHC class I expression by tumor cells along with the gene expression of IFN-γ–dependent chemokines CXCL9 and CXCL10, essential for immune cell infiltration. Furthermore, CD8+ T cells, an important source of IFN-γ, which mediate effector antitumor responses, had reduced ability to proliferate and generate IFN-γ under hypoxic conditions in vitro. Interestingly, reoxygenation restored the cytokine-producing capability of these cells. Studies performed in vivo using a mouse tumor model and the hypoxia marker EF5 demonstrated that RT could reverse the hypoxia within treated tumors. This study has identified a unique mechanism of hypoxia-induced immune suppression involving the downregulation of IFN-γ production and cellular responsiveness to this essential cytokine. These results suggest that therapies that target and reduce tumor hypoxia can potentially boost antitumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have shown that hypoxia induces a decrease in IFN-γ signaling in a mouse CRC model, leading to a decrease in MHC class I molecule expression [211].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Strategies such as hyperbaric chambers, angiogenesis inhibitors, and radiosensitizer molecules were developed to improve the oxygenation status of tumors and circumvent the problem of radiation resistance (12).”
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219 · cited 2×
“RT is widely used to treat a majority of cancers, but the presence of hypoxic regions can result in resistance to RT (4, 8–10).”
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514 · cited 1×
“Importantly, biopsies from lung, colon, brain, ovarian, head and neck, pancreas, prostate, rectum, and stomach cancers have demonstrated correlations with increased expression of hypoxia-induced protein expression and poor patient prognosis (5, 7).”
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · cited 1×
“These included the chemokines ccl28 (involved with regulatory T cell migration) (36, 37) and cxc3cl1, which increases tumor cell migration and metastasis by enhancing epithelial-to-mesenchymal transition-like phenotype (38).”
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239 · cited 6×
“In addition to Ag-specific activation, T cells undergo extensive proliferation, which occurs initially in the lymph node but also occurs in situ within the TME (44).”
InfluentialHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 1×
“It is a critical factor involved in tumor invasion and metastasis, dormancy, pH regulation, stem cell differentiation, inflammation, angiogenesis, glucose metabolism, and resistance to radiotherapy (RT) and chemotherapy (3–6).”
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660 · cited 1×
“Additionally, another study demonstrated increased production of the lytic molecules perforin and granzyme upon constitutive activation of hypoxia inducible factor-1 (HIF-1), the predominate transcription factor for hypoxia signaling, indicating that hypoxic T cells are better killers (28, 29).”
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · cited 1×
“Similarly, other in vivo studies demonstrate preferential localization of T cells away from hypoxic tumor zones, suggesting a possible immune escape mechanism used by tumor cells (20–22).”
Cited by
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
Vito, A., El-Sayes, N., & Mossman, K. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 270
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Hompland, T., Fjeldbo, C. S., & Lyng, H. (2021) · Cancers · doi:10.3390/cancers13030499 · Cited by 179
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115
Hypoxia as a Modulator of Inflammation and Immune Response in Cancer
Castillo‐Rodríguez, R. A., Trejo‐Solís, C., Cabrera‐Cano, A., Gómez‐Manzo, S., & Dávila‐Borja, V. M. (2022) · Cancers · doi:10.3390/cancers14092291 · Cited by 81
Hiraoka, N., Ino, Y., Hori, S., Yamazaki–Itoh, R., Naito, C., Shimasaki, M., Esaki, M., Nara, S., Kishi, Y., Shimada, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14514 · Cited by 69
The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT
Moon, E. J., Petersson, K., & Olcina, M. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1988178 · Cited by 63
“Interestingly, the effects on IFN-c production by T-cells appear HIF-1a independent and can be rescued by reoxygenation (into 21% O2) (Murthy et al. 2019).”
BackgroundOXPHOS inhibitors, metabolism and targeted therapies in cancer
Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59
Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation
Estéphan, H., Tailor, A., Parker, R. S., Kreamer, M., Papandreou, I., Campo, L., Easton, A., Moon, E. J., Denko, N. C., Ternette, N., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-024-00319-7 · Cited by 60
“…which are essential for recruitment of effector immune cells such as CD8 + T cells into tumors or potential decreases at the transcriptional level of MHC I expression in a HIF dependent manner in malignant cells under hypoxic (10% O 2 ) conditions (Murthy et al, 2019; Sethumadhavan et al, 2017).”
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Robles-Oteíza, C., Hastings, K., Choi, J., Sirois, I., Ravi, A., Expósito, F., de Miguel, F. J., Knight, J., López‐Giráldez, F., Choi, H., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231106 · Cited by 46
“Because hypoxia cancell-intrinsically modulate cancer cell MHC-I expression (Murthy et al., 2019; Marijt et al., 2019), we tested whether hypoxia could similarly impact MHC-II expression in LKR13 cells exposed to IFN γ under normoxic (21% O 2 ) or hypoxic (1% O 2 ) conditions in vitro.”
Mohapatra, S. R., Sadik, A., Tykocinski, L.-O., Dietze, J., Poschet, G., Heiland, I., & Opitz, C. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02762 · Cited by 40
“Furthermore, hypoxia also obstructs anti-tumor immunity by reduction of tumor cell MHC presentation and the tumor cell expression of chemokines essential for immune cell infiltration (23).”
BackgroundBenoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“HIF-1 has a negative effect on MHC-I expression, thus limiting tumor cell recognition by T cells [132,133].”
BackgroundMultifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance
Weng, C.-Y., Kao, C.-X., Chang, T., & Huang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031258 · Cited by 33
“Reintroduction of oxygen can restore the cytokine producing capacity of T cells [52].”
BackgroundRole of Hypoxia in the Interferon Response
Arnaiz, E., & Harris, A. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821816 · Cited by 30
Quan, Y., He, J., Zou, Q., Zhang, L., Sun, Q., Huang, H., Li, W., Xie, K., & Wei, F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007080 · Cited by 30
CD25+ B cells produced IL‐35 and alleviated local inflammation during experimental periodontitis
Han, Y., Yu, C., Yu, Y., & Bi, L. (2021) · Oral Diseases · doi:10.1111/odi.13939 · Cited by 27
Venkatesh, G. H., Khouzam, R. A., El‐Sayed, W., Zeinelabdin, N. A., Terry, S., & Chouaïb, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1974233 · Cited by 25
Vascular damage in tumors: a key player in stereotactic radiation therapy?
Kozin, S. V. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.002 · Cited by 21
Ross, S. H., Rollings, C. M., & Cantrell, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712402 · Cited by 17
Chaudhary, R., Slebos, R. J. C., Noel, L. C., Song, F., Poole, M. I., Hoening, D. S., Hernandez-Prera, J. C., Conejo-Garcia, J. R., Guevara-Patino, J. A., Wang, X., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0443 · Cited by 15
Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer
Velasco, M. A. D., Kura, Y., Fujita, K., & Uemura, H. (2024) · International Journal of Urology · doi:10.1111/iju.15378 · Cited by 13
Ge, H., Wang, L., Chen, W., & Wang, L. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/2960773 · Cited by 13
“IFN-γ is a crucial cytokine produced by activated T cells, natural killer cells (NK), and NK T cells in tumor microenvironment, and it exerts vital effects in coordination process [35, 36].”
BackgroundQian, Y., Zhu, X., Niu, D., Tang, Q., & Jin, C. (2025) · Oncology Letters · doi:10.3892/ol.2025.15339 · Cited by 9
“I by suppressing the activity of IFN regulatory factors (117).”
Alim, L., Adityan, S., Chen, R., Neilson, T., Coleborn, E., Wilkinson, A., He, Y., Irgam, G., Bhavsar, C., Lourie, R., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118141 · Cited by 5
Influence of Sports Training in Foothills on the Professional Athlete’s Immunity
Malsagova, K. A., Astrelina, T. A., Balakin, E. I., Кобзева, И. В., Adoeva, E. Y., Yurku, K. A., Suchkova, Y. B., Stepanov, A. A., Izotov, A., Butkova, T. V., et al. (2023) · Sports · doi:10.3390/sports11020030 · Cited by 5
“A myriad of concomitant homeostatic changes in the bodies of professional athletes contributes to the development of inflammatory processes caused by decreased absolute and relative counts of the B-cells and T-cells [3–7].”
ResultInfluentialEffect of cytotoxic CD8+ T-cells secretory proteins on hypoxic pancreatic cancer cells
Abdo, E., Ismail, M. A., Hadidi, S. A., Al-Mrahleh, M., Saleh, T., Zihlif, M., & Ababneh, N. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0311615 · Cited by 3
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
Edmondson, J. L., Reed, M. R., Fil, D., Heflin, B., McKinnon, A. T., Bauer, M., Morehead, L. C., Avaritt, N. L., Phillips, M., Taverna, S. D., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112750 · Cited by 3
“In contrast to models of acute metabolic stress, which often attribute IFN signaling to changes in antigenicity, 38,39 our findings suggest that prolonged, adaptive metabolic stress can promote tumor antigen presentation through epigenetic remodeling.”
Spatial Chromatin Accessibility Analysis of Intratumor Heterogeneity in Breast Cancer
Qian, Y., Zhu, M., Ren, C., Zhou, Y., Xu, J., Dong, L., Zhang, G., Lv, J., Lv, J., Xing, Q., et al. (2026) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzag001 · Cited by 3
“Hypoxia in the tumor core may dampen IFN-α and IFN-γ levels [57,58], while the oxygen-rich paratumoral area showed heightened immune cell activity and IFN-α and IFN-γ expression.”
Jeng, L., Shih, F., Liao, Y., Shyu, W., & Teng, C. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02975-w · Cited by 1
Transcriptional Profile Alteration of Peripheral Blood in Chronic Hypoxia
Wang, T. J., Junyue, X., Zhang, L., & Hao, Z. (2020) · Chinese Medical Sciences Journal · doi:10.24920/003598
“[40, 41] However, other tumor-related studies have shown that hypoxia enhances the antigen presentation of MHC class I.”
Singh, M., Rajput, R., Agarwal, V., Jindal, D., Pancham, P., & Srivastava, S. (2023) · Smart nanomaterials technology · doi:10.1007/978-981-99-1718-1_3 · Cited by 1
Chatterjee, M., Gu, F., Samanta, S., Rasaily, U., Thota, S. M., Varghese, D., QIU, Y., Fordwuo, L. E. E., Villanueva, H. J., McKenna, M. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702389
Fukuda, R., Fujiwara, Y., Maruyama, T., & Komohara, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1852700
Fowler, E. A., Schneider, O. L., Saif, F., & Novais, F. O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741849
Ghais, A., Rizkallah, J., Wehbeh, B. E. D., Diab, Y., Awada, A., Atwi, M., Ayoub, R., Mina, C., Rammal, F., badr, A., et al. (2026) · Cancers · doi:10.3390/cancers18172829
Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy
Pin, G., Xie, Y., Song, R., Yang, M., Lin, Z., Guan, C., Wang, Z., Wen, J., & Chen, G. (2026) · MedComm · doi:10.1002/mco2.71040
Metadata
- Authors
- Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M.
- Affiliations
- University of Rochester Medicine (US)
- University of Pennsylvania (US)
- Corresponding author
- Murthy, Aditi
- Venue
- ImmunoHorizons
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 149-160
- ISSN
- 2573-7732 (ISSN-L)
- PMC
- PMC8195309
- OpenAlex
- W2942594871
- Cited by
- 36
- References
- 50
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ImmunoHorizons (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- National Cancer Institute (R01CA028332)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor hypoxia, intratumoral hypoxia, interferon-gamma, MHC class I expression, antitumor immunity, radiotherapy, CD8+ T cells, CXCL9, CXCL10, chemokines, immune cell infiltration, tumor reoxygenation, immunosuppression, B16F0 melanoma, colon cancer cells
- MeSH terms
- Animals, Hypoxia, Disease Models, Animal, Female, Humans, Immunity, Immunohistochemistry, Interferon-gamma, Male, Neoplasms, Histocompatibility Antigens Class I, Biomarkers, Gene Expression Regulation, Neoplastic, CD8-Positive T-Lymphocytes, T-Cell Antigen Receptor Specificity, Cell Line, Tumor, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.